Navigation Links
Visikol Expands Image Analysis as a Service Capabilities
Date:10/8/2019

Imaging data sets are generated through drug discovery research projects using a wide-range of imaging modalities such as optical projection tomography, optical coherence tomography, echocardiogram, light sheet microscopy, MRI and X-ray CT. While many research groups have the capability to generate these data sets inhouse, a lot of research groups struggle with transforming these large and sometimes noisy data sets into actionable insights that allow them to make more informed decisions during the drug discovery process.

"At Visikol, we have assisted many pharma and biotech companies with making sense of large multi-dimensional data sets and extracting key quantitative metrics. We find that most off-the-shelf image analysis platforms are limited in their flexibility and a lot of research groups reach out to us when they need help with building customized image analysis solutions," described Visikol Chief Science Officer Dr. Tom Villani.

To start an image analysis project with Visikol, Clients discuss with the Visikol project team the types of end-points they are interested in and the details of their specific research question. Clients will then send along a hard drive of data or upload files to Visikol's secure cloud-based file sharing platform. From this data, Visikol can apply its 3Screen™ image analysis tools which are a suite of digital pathology algorithms designed for use with both two-dimensional and three-dimensional image data sets. These tools are ultimately used to transform the data sets provided by Clients into actionable insights that allow Clients to make more informed decisions during the drug discovery processes.

"Over the last few years, we have worked with Clients on projects ranging from analyzing 40-plex multiplex slide data sets and processing thousands of in vivo optical coherence retina imaging data sets to identifying novel image-based biomarkers such as in our recent work with Enzyvant Therapeutics," described Visikol Director of Imaging Services Dr. Graeme Gardner. While there are many digital pathology companies in the marketplace today offering services as well as off-the-shelf digital pathology solutions, Visikol has become a leader in this space through its expertise with multi-dimensional datasets, on-demand custom software development and image analysis software validation and clinical deployment.

About Visikol
Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

Read the full story at https://www.prweb.com/releases/visikol_expands_image_analysis_as_a_service_capabilities/prweb16588405.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Visikol Publishes Tissue Clearing Ebook on 3D Tissue Imaging and Analysis
2. Visikol Whole Rodent Brain Tissue Clearing and Imaging Services
3. Abcam Collaborates with Visikol to Develop New Tools for Improved Tissue Clearing and 3D Imaging
4. Visikol Releases Open Source 3Screen™ Python Library for Training Convolutional Neural Networks for Use in Digital Pathology
5. Come Visit Visikol at Society of Toxicology 2019 in Baltimore at Booth 3225
6. Visikol Launches OpenLiver™ 3D Cell Culture Models to Accelerate Drug Discovery
7. Biopredic International and Visikol Partner on Liver 3D Cell Culture Liver Development
8. Come Visit Visikol at SLAS to Learn About 3D Cell Culture Assays and Models
9. Visikol Appoints Pharmaceutical Industry Leader, Stewart Hunt, as Director of US Sales
10. Visikol Hits Key Milestone, Recognized by Forbes for Passion & Innovation
11. Visikol Co-Founder Michael Johnson named to 2017 Forbes 30 Under 30 List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2020)... ... February 13, 2020 , ... Strategic ... Report: The Laboratory Analytical & Life Science Instrumentation Industry. The report will be ... standard of market intelligence for the $70 billion laboratory market for analytical and ...
(Date:2/11/2020)... ... February 11, 2020 , ... The ... medical device accelerator in Port Covington, Baltimore. The newly formed company is developing ... addressed to manage increased demand for home dialysis treatments. The start-up company will ...
(Date:2/5/2020)... , ... February 04, 2020 , ... ... Office (USPTO) issued the company a second patent related to proprietary liquid crystal ... Allowance compliments another patent from the USPTO issued on December 3, 2019. Together, ...
Breaking Biology News(10 mins):
(Date:1/10/2020)... ... January 09, 2020 , ... A new report from ... vendor qualification process, a critical element of clinical trial set up and execution. ... vendor qualification process creates delays in initiation in 7% of clinical trials for ...
(Date:1/8/2020)... , ... January 08, 2020 , ... ... wire composites that can achieve specific properties for use in harsh environments inside ... Wire combines up to three metals or alloys to achieve specific properties ...
(Date:1/7/2020)... (PRWEB) , ... January 07, 2020 , ... Vuja De ... cancer progression and recurrence, today announced the appointments of Chand Khanna, DVM, PhD, DACVIM ... and CEO of Vuja De said, “We are delighted to welcome Chand and Lee ...
(Date:1/7/2020)... ... January 06, 2020 , ... ... second cohort of emerging biosciences ventures invited to participate in the annual program. ... develop fundable business plans and a professional network. All startups will receive an ...
Breaking Biology Technology: